Wakamoto Pharmaceutical Co., Ltd. (4512) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Wakamoto Pharmaceutical Co., Ltd. (4512:JPX), powered by AI.

Current Price
¥246
P/E Ratio
132.5
Market Cap
8.5B
Sector
Healthcare
What is the Wakamoto Pharmaceutical Co., Ltd. stock price forecast?

Wakamoto Pharmaceutical Co., Ltd. is currently trading at ¥246. View real-time AI analysis on Alpha Lenz.

What is Wakamoto Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Wakamoto Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Wakamoto Pharmaceutical Co., Ltd.'s P/E ratio?

Wakamoto Pharmaceutical Co., Ltd.'s P/E ratio is 132.5.

Wakamoto Pharmaceutical Co., Ltd.

JPX · 4512
¥246+2(+0.82%)Market closedJPX regular session 09:00–15:00 JST
Ask about Wakamoto Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Wakamoto Pharmaceutical Co., Ltd. trades at a P/E of 132.5 (premium valuation) with modest ROE of 0.5%.

Ask for details

Company Overview

Wakamoto Pharmaceutical Co., Ltd. is a company known for developing and manufacturing pharmaceutical and healthcare products, notably in Japan. Its primary focus is on producing over-the-counter (OTC) medications and pharmaceuticals that enhance digestive health, immune system function, and overall wellness. Among its key products is "Wakamoto," a digestive enzyme supplement that has gained wide recognition for aiding digestion and providing nutritional support. Beyond digestive aids, Wakamoto Pharmaceutical expands its impact across various sectors, including vitamins, nutritional supplements, and skincare products, aligning with the global trend towards preventive health care and wellness maintenance. The company's offerings are distributed through both direct consumer sales and healthcare providers, ensuring widespread access. Established in 1934, Wakamoto Pharmaceutical plays a significant role in the OTC pharmaceuticals market, leveraging its long-standing expertise and quality assurance practices. Its contributions to public health and emphasis on combining traditional and innovative healthcare solutions highlight its importance in the pharmaceutical industry and its commitment to enhancing quality of life for its consumers.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees403

Company Statistics

FY 2025

Profile

¥8,537,676,000Market Cap
¥7,789,461,000Revenue
0.00Shares Out
403Employees

Margins

46.50%Gross
0.29%EBITDA
-5.88%Operating
0.10%Pre-Tax
0.83%Net

Valuation

132.49P/E
0.74P/B
1.10EV/Sales
256.94EV/EBITDA
-7.84P/FCF

Growth (CAGR)

-2.42%Rev 3Yr
-6.53%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
-35.36%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

0.42%ROA
0.55%ROE
0.05%ROIC

Financial Health

¥2,954,759,000Cash & Cash Equivalents
¥437,600,000Net Debt
29.22%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Wakamoto Pharmaceutical Co., Ltd. (ticker: 4512) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 403 employees. Market cap is $8.5B.

The current price is 246 with a P/E ratio of 132.49x and P/B of 0.74x.

ROE is 0.55% and operating margin is -5.88%. Annual revenue is $7.8B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Wakamoto Pharmaceutical Co., Ltd. (4512) Stock Forecast 2026 ¥246 — Price, Financials & Analyst Targets | Alpha Lenz